Signals, Powered By EquityPandit
Caplin Point Laboratories has got the Establishment Inspection Report from the US health regulator for its Gummidopoondi facility in Chennai.
Caplin Point Laboratories has said in a BSE filing that “The company has received the Establishment Inspection Report (EIR) from USFDA (The United States Food and Drug Administration) for inspection carried out during Oct 21-27, 2016, at its sterile injectable plant at Gummidopoondi in Tamil Nadu.”
Caplin Point Laboratories Chairman C C Paarthipan has said that “This will pave the way for our entry into the largest pharma market in the world.”
